retatrutide news today recency 3 🚨Breaking: Retatrutide's first Phase T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Michael Weintraub, MD on X:

N., & Dhillo, W

When GLP-1 is simultaneously active, glucagon promotes fat burning without causing problematic blood sugar spikes

Key findings from clinical research include: The proportion of lean mass loss with GLP-1 medications appears comparable to that seen with lifestyle interventions alone Fat mass loss consistently exceeds lean mass loss, improving the overall fat-to-lean ratio Some evidence suggests improvements in physical function despite some lean mass reduction, likely due to decreased mechanical load and improved metabolic health, though more research is needed Individual responses vary, with some patients experiencing greater lean mass preservation than others A 2023 systematic review published in Obesity Reviews concluded that whilst lean mass decreases during GLP-1 treatment, this reflects the expected consequences of weight loss rather than a direct catabolic effect of the medication

Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency

nslin duyarlln artrr ve Tip 2 diyabete ilerlemeyi nlemeye yardmc olur Polikistik Over Sendromu (PKOS)